Miguel Mantilla-Villamizar
Internal Medicine · The Villages, FLNPI 1063864346
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 223 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,361 and has fallen 92.3% since, to $105 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 223 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$681
- AstraZeneca$680
- AbbVie$675
- Boehringer Ingelheim$408
- Gilead$350
- Exact Sciences$253
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,57499%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 38 | $681 |
| AstraZeneca | 21 | $680 |
| AbbVie | 35 | $675 |
| Boehringer Ingelheim | 20 | $408 |
| Gilead | 20 | $350 |
| Exact Sciences | 14 | $253 |
| Bayer | 7 | $188 |
| Lilly USA, LLC | 9 | $176 |
| Amgen | 9 | $175 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $165 |
| Novo Nordisk | 8 | $155 |
| Averitas Pharma Inc. | 1 | $105 |
| GSK | 4 | $98 |
| Ardelyx, Inc. | 3 | $57 |
| Phathom Pharmaceuticals, Inc. | 3 | $56 |
| Novartis | 2 | $42 |
| Medtronic(2 entities) | 2 | $33 |
| Viiv Healthcare Company | 2 | $32 |
| Redhill Biopharma Inc. | 2 | $31 |
| Seqirus USA Inc | 1 | $25 |
| Stryker | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Alkermes, Inc. | 1 | $20 |
| Mannkind Corporation | 1 | $20 |
| Merck | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Bausch Health US, LLC | 1 | $13 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,597 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 163 | $233,538 |
| FarxigaDapagliflozin Propanediol | 157 | $215,446 |
| OzempicSemaglutide | 100 | $152,342 |
| JanuviaSitagliptin Phosphate | 95 | $132,333 |
| TradjentaLinagliptin | 62 | $84,899 |
| TrulicityDulaglutide | 42 | $52,952 |
| LinzessLinaclotide | 40 | $37,247 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $27,546 |
| ProliaDenosumab | 12 | $21,048 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $16,935 |
| Repatha SyringeEvolocumab | 25 | $13,677 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $13,605 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $13,487 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 90 | $9,513 |
| RectivNitroglycerin | 12 | $7,736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $408 | $318,436225 claims |
| AstraZenecaFarxiga, Symbicort | $680 | $220,543181 claims |
| MerckJanuvia, Janumet Xr | $18 | $159,879113 claims |
| Novo NordiskOzempic | $155 | $152,342100 claims |
| Lilly USA, LLCTrulicity | $176 | $52,95242 claims |
| AbbVieLinzess | $675 | $37,24740 claims |
| AmgenProlia | $175 | $21,04812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in The Villages
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.